Retrospective studies suggest that HER2+ patients with T1aN0 or T1bN0 tumours have a significantly worse survival than HER2− patients with similar tumour characteristics (Banerjee and Smith, 2010). This evidence concerns the gene ERBB2 and neoplasm.